Table 1 Characteristics of ten-year and 2015-year cohorts
Characteristics | Ten-year cohort (2009–2019) | 2015-year cohort (2015) | |||
|---|---|---|---|---|---|
Number of cases | Proportion of study population | Number of cases | Proportion of study population | ||
Totala | 275,900 | 100.0% | 45,675 | 100.0% | |
Center / Vendor | MK / IMS Giotto | 83,410 | 30.2% | 10,462 | 22.9% |
NUH / GE | 69,045 | 25.0% | 10,983 | 24.0% | |
LTHT / Hologic | 64,645 | 23.4% | 10,717 | 23.5% | |
ULH / Siemens | 58,800 | 21.3% | 13,513 | 29.6% | |
Age | < 40 | 483 | 0.2% | 5 | < 0.1% |
40—49 | 37,696 | 13.7% | 5,575 | 12.2% | |
50—59 | 114,524 | 41.5% | 19,399 | 42.5% | |
60—69 | 98,289 | 35.6% | 16,772 | 36.7% | |
70—79 | 23,359 | 8.5% | 3,702 | 8.1% | |
80—89 | 1,534 | 0.6% | 221 | 0.5% | |
> 90 | 15 | < 0.1% | 1 | < 0.1% | |
Positives | Total positivesb | 2,683 | 0.97% | 457 | 1.00% |
Screen-detected positives | 2,310 | 0.84% | 365 | 0.80% | |
Interval cancers (ICs) | 373 | 0.14% | 92 | 0.20% | |
Three-year ICs from UK | 289 | 0.10% | 80 | 0.18% | |
Two-year ICs from HU | 84 | 0.03% | 12 | 0.03% | |